An experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and preventing harmful toxins from damaging the liver. The discovery could open the door ...

A global medical technology company has acquired AVS, maker of a device treating arterial calcification, to expand patient ...

Do you have brittle bones, get small cuts that won't stop bleeding, and bruise easily? You might be vitamin K deficient.

Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving gut health, according to a study published in The Journal of Clinical ...

The SKYWARD programme includes two planned prospective, multi-centre, single-arm IDE studies.

Researchers discovered that a potential drug developed at Michigan Medicine treats severe fatty liver disease by improving ...

Seven internationally recognized nephrology experts join R1's Scientific Advisory BoardStrengthens scientific and clinical guidance as AP306 ...

Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is an increasingly recognized disorder associated with high mortality rates. The pathomechanisms of CUA are only partially understood ...

Endologix LLC announced 36-month results from the DETOUR2 clinical trial evaluating percutaneous transmural arterial bypass ...

A recent retrospective study of 504 patients found that in-hospital mortality was not significantly affected by reduced heart ...

J&J is working to expand use of Shockwave’s technology as competition in intravascular lithotripsy builds from companies like ...